Nesrin Turhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nesrin Turhan has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Dilek Oguz
2 shared publications- Erkin Oztas
Department of Gastroenterology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
2 shared publications - Ibrahim Koral Onal
Hacettepe University Medical School
2 shared publications Mevlut Kurt
2 shared publications- Mevlut Kurt
Department of Gastroenterology, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
2 shared publications Abdurrahim Yee Sayilir
1 shared publication
Latest Publications
- Open Access
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5290
Clinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study
Background/Objective: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with limited therapeutic options and poor survival outcomes. Recent advances in molecular oncology have highlighted the significance of isocitrate dehydrogenase 1 (IDH1) mutations as potential therapeutic targets. However, data on the prevalence and prognostic implications of IDH1 mutations in patients with iCCA are scarce. This study aimed to retrospectively investigate the IDH1 mutation rate, histopathological features, and survival outcomes of patients with iCCA. Methods: We retrospectively analyzed 88 patients diagnosed and treated between 2005 and 2025 at two tertiary oncology centers. Clinical, pathological, and survival data were obtained from the institutional oncology archives and national population databases. IDH1 mutation status was evaluated using polymerase chain reaction and next-generation sequencing of paraffin-embedded tissue samples. Results: A total of 88 patients with iCCA were included, with a median age of 62 years, and 62.5% were male. Abdominal pain was the most common presenting symptom (67%). The most frequent stages at diagnosis were stage IB and stage IIIB (22.7% each). Histopathologically, the small-duct subtype (55.7%), nodular morphology (67.0%), and solitary tumors (79.5%) predominated. IDH1 mutation was detected in 2.3% of patients. Curative surgery was performed in 78.2% of cases and was more common in early-stage disease. Gemcitabine–capecitabine was the most frequently used adjuvant regimen, whereas gemcitabine–cisplatin was the most common palliative treatment regimen. Median overall survival differed significantly by albumin-bilirubin (ALBI) grade, with 40.1, 11.1, and 4.4 months for grades 1, 2, and 3, respectively (p < 0.001). Conclusions: In this multicenter cohort, iCCA was characterized by diverse clinicopathological features and treatment approaches. Surgical resection remains the main treatment modality for patients with localized disease, whereas systemic therapies are more frequently used in advanced stages. The findings highlight the prognostic relevance of baseline clinical and biochemical characteristics and may improve risk stratification in patients with iCCA.
- 7 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5290
Open AccessClinicopathological Features of Intrahepatic Cholangiocarcinoma with Assessment of IDH1 Mutation: A Two-Center Retrospective Study
Background/Objective: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with limited therapeutic options and poor survival outcomes. Recent advances in molecular oncology have highlighted the significance of isocitrate dehydrogenase 1 (IDH1) mutations as potential therapeutic targets. However, data on the prevalence and prognostic implications of IDH1 mutations in patients with iCCA are scarce. This study aimed to retrospectively investigate the IDH1 mutation rate, histopathological features, and survival outcomes of patients with iCCA. Methods: We retrospectively analyzed 88 patients diagnosed and treated between 2005 and 2025 at two tertiary oncology centers. Clinical, pathological, and survival data were obtained from the institutional oncology archives and national population databases. IDH1 mutation status was evaluated using polymerase chain reaction and next-generation sequencing of paraffin-embedded tissue samples. Results: A total of 88 patients with iCCA were included, with a median age of 62 years, and 62.5% were male. Abdominal pain was the most common presenting symptom (67%). The most frequent stages at diagnosis were stage IB and stage IIIB (22.7% each). Histopathologically, the small-duct subtype (55.7%), nodular morphology (67.0%), and solitary tumors (79.5%) predominated. IDH1 mutation was detected in 2.3% of patients. Curative surgery was performed in 78.2% of cases and was more common in early-stage disease. Gemcitabine–capecitabine was the most frequently used adjuvant regimen, whereas gemcitabine–cisplatin was the most common palliative treatment regimen. Median overall survival differed significantly by albumin-bilirubin (ALBI) grade, with 40.1, 11.1, and 4.4 months for grades 1, 2, and 3, respectively (p < 0.001). Conclusions: In this multicenter cohort, iCCA was characterized by diverse clinicopathological features and treatment approaches. Surgical resection remains the main treatment modality for patients with localized disease, whereas systemic therapies are more frequently used in advanced stages. The findings highlight the prognostic relevance of baseline clinical and biochemical characteristics and may improve risk stratification in patients with iCCA.
- Open Access
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45515
Utilizing CT-derived extracellular volume fraction to distinguish hepatocellular adenoma from focal nodular hyperplasia
This study evaluates the efficacy of computed tomography derived extracellular volume (ECV) fraction in differentiating focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA). Forty-eight pathologically proven lesions (21 HCA and 27 FNH) in 41 patients (18 with HCA and 23 with FNH) were retrospectively examined in this single-center study conducted between March 2015 and September 2023. The ECV fraction was calculated from unenhanced and equilibrium phase computed tomography images. Receiver operating characteristic curve analysis was used to determine the best discrimination between FNH and HCA. The study population consisted of patients diagnosed with HCA (16.7% male, mean age 34.2 ± 10.3 years) and FNH (26.1% male, mean age 41.6 ± 9 years). The ECV fraction of the FNH group was significantly higher than that of the HCA group (37.7%±8.8% vs 26.7% [interquartile range: 22.5%–31%], P = .001). The optimal cutoff value for the ECV fraction in differentiating FNH from HCA was determined to be 32.25%, with 76.5% sensitivity and 78.9% specificity (area under the curve, 0.824; 95% confidence interval [CI]: 0.675–0.972, P = .001). The interobserver reliability of ECV fraction measurement was excellent for both HCA (intraclass correlation coefficient, 0.884; 95% CI: 0.724–0.953, P = .001) and FNH (intraclass correlation coefficient, 0.915; 95% CI: 0.764–0.969, P < .001). ECV fraction demonstrated high performance and efficacy as a potential diagnostic tool for differentiating FNH from HCA.
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45515
Open AccessUtilizing CT-derived extracellular volume fraction to distinguish hepatocellular adenoma from focal nodular hyperplasia
This study evaluates the efficacy of computed tomography derived extracellular volume (ECV) fraction in differentiating focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA). Forty-eight pathologically proven lesions (21 HCA and 27 FNH) in 41 patients (18 with HCA and 23 with FNH) were retrospectively examined in this single-center study conducted between March 2015 and September 2023. The ECV fraction was calculated from unenhanced and equilibrium phase computed tomography images. Receiver operating characteristic curve analysis was used to determine the best discrimination between FNH and HCA. The study population consisted of patients diagnosed with HCA (16.7% male, mean age 34.2 ± 10.3 years) and FNH (26.1% male, mean age 41.6 ± 9 years). The ECV fraction of the FNH group was significantly higher than that of the HCA group (37.7%±8.8% vs 26.7% [interquartile range: 22.5%–31%], P = .001). The optimal cutoff value for the ECV fraction in differentiating FNH from HCA was determined to be 32.25%, with 76.5% sensitivity and 78.9% specificity (area under the curve, 0.824; 95% confidence interval [CI]: 0.675–0.972, P = .001). The interobserver reliability of ECV fraction measurement was excellent for both HCA (intraclass correlation coefficient, 0.884; 95% CI: 0.724–0.953, P = .001) and FNH (intraclass correlation coefficient, 0.915; 95% CI: 0.764–0.969, P < .001). ECV fraction demonstrated high performance and efficacy as a potential diagnostic tool for differentiating FNH from HCA.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A rare case of acromegaly concomitant with pancreatic adenocarcinoma
Background and aim: Acromegaly is a rare endocrine disease and is associated with an increased prevalence of colorectal cancer and pre-malignant tubular adenomas, and also may be associated with other organ malignancies such as breast and thyroid. We report a rare case of acromegaly concomitant with adenocarcinoma arising from pancreas. Case report: A 52-year-old man who was diagnosed with acromegaly two years ago referred our outpatient clinic. After diagnosis, transsphenoidal surgery was performed. Surgery was not reduced serum growht hormone (GH) and insulin-like growth factor 1 (IGF-1) to normal, therefore somatostatin analog treatment was started. After this treatment, glucose-suppressed GH concentration was <1.0 ng/ml and serum IGF-1 concentration normal for age and gender. He was admitted to out-patient clinic with abdominal pain about 1 month ago. Abdomen CT showed that 44X26 mm mm mass lesion in the body and tail of the pancreas and multiple metastatic lesions in the liver. Upper gastrointestinal endoscopy and colonoscopy showed that erosive gastritis and polyps in the colon, respectively. After these imaging studies, endoscopic ultrasound-guided needle aspiration biopsy was performed to the mass lesions in the tail of the pancreas. Pathological examination revealed a adenocarcinoma arising from the pancreas. Conclusions: The patients with acromegaly have an increased risk of benign and malignant neoplasms, These situation may be related with increased circulating levels of IGF-1 because of proliferative and anti-apoptotic activity of IGF-1.It is important to consider pancreatic adenocarcinoma in the presence of acromegaly.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A rare case of acromegaly concomitant with pancreatic adenocarcinoma
Background and aim: Acromegaly is a rare endocrine disease and is associated with an increased prevalence of colorectal cancer and pre-malignant tubular adenomas, and also may be associated with other organ malignancies such as breast and thyroid. We report a rare case of acromegaly concomitant with adenocarcinoma arising from pancreas. Case report: A 52-year-old man who was diagnosed with acromegaly two years ago referred our outpatient clinic. After diagnosis, transsphenoidal surgery was performed. Surgery was not reduced serum growht hormone (GH) and insulin-like growth factor 1 (IGF-1) to normal, therefore somatostatin analog treatment was started. After this treatment, glucose-suppressed GH concentration was <1.0 ng/ml and serum IGF-1 concentration normal for age and gender. He was admitted to out-patient clinic with abdominal pain about 1 month ago. Abdomen CT showed that 44X26 mm mm mass lesion in the body and tail of the pancreas and multiple metastatic lesions in the liver. Upper gastrointestinal endoscopy and colonoscopy showed that erosive gastritis and polyps in the colon, respectively. After these imaging studies, endoscopic ultrasound-guided needle aspiration biopsy was performed to the mass lesions in the tail of the pancreas. Pathological examination revealed a adenocarcinoma arising from the pancreas. Conclusions: The patients with acromegaly have an increased risk of benign and malignant neoplasms, These situation may be related with increased circulating levels of IGF-1 because of proliferative and anti-apoptotic activity of IGF-1.It is important to consider pancreatic adenocarcinoma in the presence of acromegaly.
- 12 June 2012
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 59 (117) , 1580-2
The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
Hepatocellular carcinoma (HCC) has poor long-term prognosis so we need new diagnostic techniques and markers to detect HCC in the early phases. The aim of this study was to analyze the levels of serum mean platelet volume in HCC. The clinical data of 230 subjects with normal, chronic hepatitis, cirrhosis and HCC were retrospectively analyzed at our hospital between January 2009 and December 2009. The levels of MPV were determined in patients with liver disease and compared between patient groups and with healthy persons. Serum MPV levels were significantly increased compared to the patients with chronic hepatitis, cirrhosis, and the control group (p<0.01). The cut-off value for MPV for the detection of HCC in cirrhotic patients was calculated as ≥9.2fl using ROC analysis [Sensitivity: 68.3%, specificity: 62.1%, AUC: 0.676 (0.580-0.773), p<0.001]. Additionally, serum MPV levels show higher sensitivity for diagnosis of HCC than AFP. An AFP of more than 7.4IU/mL and an MPV of ≥9.2fl, both put together, had a specificity of 95.2%, while when used separately, they have a sensitivity of 87.5%. MPV may be a potential or adjunctive marker of HCC in patients with chronic liver disease.
- 12 June 2012
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 59 (117) , 1580-2
The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease.
Hepatocellular carcinoma (HCC) has poor long-term prognosis so we need new diagnostic techniques and markers to detect HCC in the early phases. The aim of this study was to analyze the levels of serum mean platelet volume in HCC. The clinical data of 230 subjects with normal, chronic hepatitis, cirrhosis and HCC were retrospectively analyzed at our hospital between January 2009 and December 2009. The levels of MPV were determined in patients with liver disease and compared between patient groups and with healthy persons. Serum MPV levels were significantly increased compared to the patients with chronic hepatitis, cirrhosis, and the control group (p<0.01). The cut-off value for MPV for the detection of HCC in cirrhotic patients was calculated as ≥9.2fl using ROC analysis [Sensitivity: 68.3%, specificity: 62.1%, AUC: 0.676 (0.580-0.773), p<0.001]. Additionally, serum MPV levels show higher sensitivity for diagnosis of HCC than AFP. An AFP of more than 7.4IU/mL and an MPV of ≥9.2fl, both put together, had a specificity of 95.2%, while when used separately, they have a sensitivity of 87.5%. MPV may be a potential or adjunctive marker of HCC in patients with chronic liver disease.
- 1 July 2011
- Published by Elsevier in Cardiovascular Pathology
- Vol. 20 (4) , 232-237
Primary cardiac undifferentiated sarcoma: role of intraoperative imprint cytology and frozen section of two cases
- 1 July 2011
- Published by Elsevier in Cardiovascular Pathology
- Vol. 20 (4) , 232-237
Primary cardiac undifferentiated sarcoma: role of intraoperative imprint cytology and frozen section of two cases
- 1 June 2011
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (6) , 359-365
Hepatic granulomas: A clinicopathologic analysis of 86 cases
- 1 June 2011
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (6) , 359-365
Hepatic granulomas: A clinicopathologic analysis of 86 cases
- 10 September 2010
- Published by Wiley in Diagnostic Cytopathology
- Vol. 39 (11) , 808-817
Endoscopic ultrasonography‐guided fine‐needle aspiration for diagnosing upper gastrointestinal submucosal lesions: A prospective study of 50 cases
The objective was to assess EUS‐FNA for diagnosing intramural upper GI tract lesions. The subjects were 50 patients (21M/29F) with upper GI submucosal lesions who underwent EUS‐FNA at a referral center for GI system over a 12‐month period. All cases were followed for 1 year after initial EUS‐FNA. Cytologic diagnoses were categorized as benign, malignant, suspicious for malignancy, mesenchymal tumor, endocrine tumor, or nondiagnostic. All tumors were assessed for various cytomorphologic features. The accuracy of the initial FNA diagnoses was evaluated for each patient who also underwent subsequent histopathological examination of a core biopsy and/or surgical biopsy/resection material of the same lesion. According to the site of the lesions; while 84% of all esophageal lesions were diagnosed as mesenchymal; 67% of all gastric lesions were mesenchymal. The sole lesion was nonmesenchymal (benign cyst) in duodenum. The sensitivity, specificity, positive and negative predictive values, and accuracy of EUS‐FNA for diagnosing submucosal mesenchymal tumors of the upper GI tract were 82.9, 73.3, 87.9, 64.7, and 80%, respectively. The corresponding values for nonmesenchymal lesions were 100, 85.7, 80, 100, and 90.9%. Our experience confirms that EUS‐FNA is an extremely valuable tool for diagnosing submucosal lesions of the upper GI, and is particularly useful in cases where endoscopic forceps biopsy does not lead to diagnosis. Optimal results can be yielded by a close working relationship between the gastroenterologist and pathologist. Diagn. Cytopathol. 2011.
- 10 September 2010
- Published by Wiley in Diagnostic Cytopathology
- Vol. 39 (11) , 808-817
Endoscopic ultrasonography‐guided fine‐needle aspiration for diagnosing upper gastrointestinal submucosal lesions: A prospective study of 50 cases
The objective was to assess EUS‐FNA for diagnosing intramural upper GI tract lesions. The subjects were 50 patients (21M/29F) with upper GI submucosal lesions who underwent EUS‐FNA at a referral center for GI system over a 12‐month period. All cases were followed for 1 year after initial EUS‐FNA. Cytologic diagnoses were categorized as benign, malignant, suspicious for malignancy, mesenchymal tumor, endocrine tumor, or nondiagnostic. All tumors were assessed for various cytomorphologic features. The accuracy of the initial FNA diagnoses was evaluated for each patient who also underwent subsequent histopathological examination of a core biopsy and/or surgical biopsy/resection material of the same lesion. According to the site of the lesions; while 84% of all esophageal lesions were diagnosed as mesenchymal; 67% of all gastric lesions were mesenchymal. The sole lesion was nonmesenchymal (benign cyst) in duodenum. The sensitivity, specificity, positive and negative predictive values, and accuracy of EUS‐FNA for diagnosing submucosal mesenchymal tumors of the upper GI tract were 82.9, 73.3, 87.9, 64.7, and 80%, respectively. The corresponding values for nonmesenchymal lesions were 100, 85.7, 80, 100, and 90.9%. Our experience confirms that EUS‐FNA is an extremely valuable tool for diagnosing submucosal lesions of the upper GI, and is particularly useful in cases where endoscopic forceps biopsy does not lead to diagnosis. Optimal results can be yielded by a close working relationship between the gastroenterologist and pathologist. Diagn. Cytopathol. 2011.
- 19 April 2010
- Published by Wiley in Echocardiography
- Vol. 27 (4) , 466-469
Multisite Infective Endocarditis/Endarteritis in a Young Peripartum Patient with Patent Ductus Arteriosus and Rheumatic Heart Valve Disease: A Case Report
Infective endocarditis (IE) is rarely seen in pregnancy and puerperal period, and generally occurs in patients with preexisting heart disease or intravenous drug abuse. In this report, we describe a case of a 27-year-old patient with missed diagnosis of rheumatic heart disease and a moderate size patent ductus arteriosus, in whom multisite culture-negative IE/pulmonary endarteritis developed after uncomplicated vaginal delivery.
- 19 April 2010
- Published by Wiley in Echocardiography
- Vol. 27 (4) , 466-469
Multisite Infective Endocarditis/Endarteritis in a Young Peripartum Patient with Patent Ductus Arteriosus and Rheumatic Heart Valve Disease: A Case Report
Infective endocarditis (IE) is rarely seen in pregnancy and puerperal period, and generally occurs in patients with preexisting heart disease or intravenous drug abuse. In this report, we describe a case of a 27-year-old patient with missed diagnosis of rheumatic heart disease and a moderate size patent ductus arteriosus, in whom multisite culture-negative IE/pulmonary endarteritis developed after uncomplicated vaginal delivery.
- 12 November 2009
- Vol. 72 (3) , 377-8
Hepatocellular carcinoma in an adult patient with type IV glycogen storage disease.
- 12 November 2009
- Vol. 72 (3) , 377-8
Hepatocellular carcinoma in an adult patient with type IV glycogen storage disease.